One more fallen star-ZODIAC and its implications

The Lancet Oncology

Volumn 11, Issue 7, 2010, Pages 604-605

  Stinchcombe, T E ^a   Govindan, R ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; VANDETANIB; ANTINEOPLASTIC AGENT; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TAXOID;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NOTE; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; BIOASSAY; DISEASE FREE SURVIVAL; LUNG TUMOR; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; LUNG NEOPLASMS; PIPERIDINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TAXOIDS;

EID: 77954936540     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70149-2     Document Type: Note

References (6)

1. Bang YJ, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2010, 28:3. (abstr).
2. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
4. Herbst RS, Sun Y, Eberhardt WEE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11:619-626.
5. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2007, 25:4270-4277.
6. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005, 23:7199-7206.